Statement from FDA Commissioner Scott Gottlieb, M.D., on new policies to reduce the ability of brand drug makers to use REMS programs as a way to block timely generic drug entry, helping promote competition and access
FDA Commissioner on new policies to reduce ability of brand drug makers to use REMS programs to block timely generic drug entry
